{"acquisitions":[],"changes":[],"country":"US","description":"Discovers small-molecule cancer drugs including BH-30643, a mutant-selective OMNI-EGFR inhibitor, and BH-30236, a CLK inhibitor for relapsed AML and MDS. Built for patients with EGFR/HER2-mutant NSCLC and high-risk hematologic cancers. Co-founded by J. Jean Cui, the chemist behind crizotinib, lorlatinib and repotrectinib, with $257M raised to date.","domain":"blossomhilltx.com","employees":null,"founded":2020,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":32.71742,"lng":-117.162772,"location":"San Diego, USA","multiples":[],"name":"BlossomHill Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":84000000,"connectionsAmong":[],"currency":"USD","date":"2025-12-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"blossomhilltx-com-2025-12-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-17","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"blossomhilltx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-17","status":"attributed","url":null},{"fact":"existence","publisher":"blossomhilltx.com","retrievedAt":"2026-05-17","status":"self-reported","url":"https://blossomhilltx.com"},{"fact":"description","publisher":"blossomhilltx.com","retrievedAt":"2026-05-17","status":"self-reported","url":"https://blossomhilltx.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":257000000,"traction":[],"updatedAt":"2026-05-17","valuations":[]}